Breast Cancer Stamp Debuts in June

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

WASHINGTON--The US Postal Service will release its Breast Cancer Awareness stamp on June 15, in conjunction with the 1996 National Race for the Cure, the 5K race that raises money to fund breast cancer research, education, treatment, and screening.

WASHINGTON--The US Postal Service will release its Breast CancerAwareness stamp on June 15, in conjunction with the 1996 NationalRace for the Cure, the 5K race that raises money to fund breastcancer research, education, treatment, and screening.

Race for the Cure was founded by the Susan G. Komen Breast CancerFoundation, established in 1982 by Nancy Brinker in memory ofher sister Susan G. Komen, who died of breast cancer at the ageof 36.

Sale of the stamp will launch a 4-month public service campaignduring which the Postal Service will join with the YWCA's ENCOREplusprogram, the American Cancer Society, Lifetime Television, andseveral breast cancer groups in providing information and mammographyscreenings at neighborhood post offices and other community locations.

The NCI's Cancer Information Service toll-free number (1-800-4-CANCER)will be printed on the top border of each sheet of 20 stamps.One hundred million stamps will be printed.

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.